Anplag Tablets 90Mg (1 Strip = 10 Tablets)

Patients treated with Ticagrelor may develop dyspnea. Dyspnea is usually mild to moderate in intensity and often resolves during continued treatment, but lead to drug discontinuation . If a patient develops new, prolonged, or worsened dyspnea that is determined to be related to Ticagrelor, no specific treatment is required; continue Ticagrelor without interruption if possible. In the case of intolerable dyspnea requiring discontinuation of Ticagrelor, consider prescribing another antiplatelet agent.
Discontinuation of Ticagrelor will increase the risk of myocardial infarction, stroke, and death. If Ticagrelor must be temporarily discontinued (e.g., to treat bleeding or for significant surgery), restart it as soon as possible. When possible, interrupt therapy with Ticagrelor for five days prior to surgery that has a major risk of bleeding. Resume Ticagrelor as soon as hemostasis is achieved.
Only limited information is available for use in patients with moderate hepatic impairment. Dose adjustments are not recommended but ticagrelor is advised to be used with caution.